MAPLE-HCM

• Research type

  Research Study

• Full title

  A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

• IRAS ID

  1007788

• Contact name

  Rachel Melman

• Contact email

  regaffairs@cytokinetics.com

• Sponsor organisation

  Cytokinetics, Inc.

• Clinicaltrials.gov Identifier

  NCT05767346

• Research summary

  The purpose of this study is to compare the potential side effects and effectiveness of aficamten with the beta-blocker, metoprolol succinate (metoprolol), in participants with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is an investigational (experimental) research medicine.

  Participants will receive either aficamten or metoprolol for a total of 24 weeks. The effectiveness of both medicines will be compared by measuring participants’ ability to exercise, heart failure symptoms, and using echocardiograms to look at heart structure.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  23/EM/0222

• Date of REC Opinion

  17 Oct 2023

• REC opinion

  Further Information Favourable Opinion